BMO Capital Downgrades BioNTech to Market Perform, Lowers Price Target to $105
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsDowngradesPrice Target
BMO Capital analyst Evan Seigerman downgrades BioNTech (NASDAQ:BNTX) from Outperform to Market Perform and lowers the price target from $128 to $105.
BMO Capital analyst Evan Seigerman downgrades BioNTech (NASDAQ:BNTX) from Outperform to Market Perform and lowers the price target from $128 to $105.